Important pharmacy news and late-breaking industry information updated daily.
The APhA Foundation’s Pinnacle Awards ceremony had a new location this year: cyberspace.
APhA is warning about potential fallout from a new FDA rule, published September 25, that sanctions the import of prescription medicines from Canada. The Trump administration asserts that Americans will save money on their medications, but APhA fears the rule will compromise patient safety.
A third of parents do not plan to have their children vaccinated against influenza this year, according to the new National Poll on Children's Health, despite the added risk of COVID-19 this year.
A new evidence-based guideline from the American Thoracic Society addresses several pharmacotherapy-initiation questions for treating tobacco use and dependence. The overall message is a recommendation in favor of varenicline over other forms of monotherapy.
During a speech in Charlotte, NC, on Thursday, President Trump said his administration would mail discount cards to 33 million Medicare beneficiaries to help pay for the cost of prescription drugs. He said these cards could be used to help pay for up to $200 in prescription drug costs. CMS would be responsible for implementing the plan.
At a Senate hearing Wednesday, four top U.S. health officials said they would readily get vaccinated against COVID-19 if the FDA were to approve a vaccine.
FDA will likely soon issue guidance on stricter standards for an emergency use authorization (EUA) of a COVID-19 vaccine in an effort to enhance transparency and strengthen public trust. Doing so could make it more challenging for any vaccine candidate to be cleared prior to Election Day on November 3, experts say.
The APhA Board of Trustees is committed to combating behaviors that undermine any member of the pharmacy profession.
A new report by the Government Accountability Office (GAO) warns that shortages of supplies and equipment are affecting the nation's COVID-19 response.
In late August, FDA approved labeling changes on hydrochlorothiazide (HCTZ) to inform clinicians and patients about a small risk of developing non-melanoma skin cancer—basal cell skin cancer or squamous cell skin cancer—associated with the use of HCTZ. At the same time, FDA is encouraging patients to protect their skin from the sun.